These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31985301)

  • 21. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
    Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
    J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
    Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
    Petersen B; Lebwohl M
    J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
    Tanghetti EA; Bhatia N; Drew S; Jacobson A
    J Drugs Dermatol; 2021 Aug; 20(8):829-836. PubMed ID: 34397206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
    Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
    J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
    J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
    Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
    J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
    Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
    J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
    Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
    Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
    Tanghetti EA; Stein Gold L; Del Rosso JQ; Lin T; Angel A; Pillai R
    J Dermatolog Treat; 2021 Jun; 32(4):391-398. PubMed ID: 31522563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
    Asche CV; Kim M; Feldman SR; Zografos P; Lu M
    J Med Econ; 2017 Sep; 20(9):1000-1006. PubMed ID: 28581873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.
    Gallo L; Megna M; Cirillo T; Caterino P; Lodi G; Mozzillo R; Dente V; Balato A
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1312-1315. PubMed ID: 30767288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
    Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
    Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
    Balak DMW; Carrascosa JM; Gregoriou S; Calzavara-Pinton P; Bewley A; Antunes J; Nyeland ME; Viola MG; Sawyer LM; Becla L
    J Dermatolog Treat; 2021 Nov; 32(7):701-708. PubMed ID: 31940225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tazarotene/Betamethasone Dipropionate Cream in Patients with Plaque Psoriasis: Results of a Prospective, Multicenter, Observational Study.
    He C; Jin H; Liu X; Hu F; Zhang L; Zhang S; He Y; Yang X; Chen H; Wang X; Ji C; Lv C; Miao G; Li X; Diao Q; Li L; Li X; Li Y; Wang R; Zhang L; Zhou X; Xia X; Yan M; Song J; Zhang R; Geng L; Zheng M; Lu Q; Lu T; Shi Y; Jing H; Zhang X; Shi J; Xia J; Gao Y; Wang Y
    Dermatology; 2021; 237(4):603-610. PubMed ID: 33352561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
    Bagel J; Zapata J; Nelson E
    J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
    Hashim PW; Nia JK; Terrano D; Goldenberg G; Kircik LH
    J Drugs Dermatol; 2017 Aug; 16(8):747-752. PubMed ID: 28809989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis.
    Blauvelt A; Green LJ; Lebwohl MG; Yamauchi PS; Lin T; Martin G; Pillai R
    J Drugs Dermatol; 2019 Mar; 18(3):297-299. PubMed ID: 30909352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.